The Global Allergy Immunotherapy Market is projected to reach $4,022.41 million by 2028, from a value of $2,116.00 million in 2022, by registering a CAGR of 11.3% during the forecast period. Increase in occurrence of allergic diseases, high demand for innovative allergic treatment procedures, rising screening for allergy and reimbursement scenario, higher R&D activities for novel therapies, and increase in the number of pipeline goods are the major factors propelling the growth of the market. However, lack of awareness among patients and side effects associated with allergic immunotherapy are hampering market growth. Moreover, increase in personal disposable income of the consumers which enables them to spend more for the allergy-related treatments are creating ample opportunities across the globe.
Recent Developments
In February 2020, Aimmune Therapeutics, Inc., a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, announced that Nestlé Health Science would make an additional equity investment of USD 200 million in Aimmune, taking Nestlés total investment in the company to date to USD 473 million.
In October 2019, Stallergenes Greer Ltd. collaborated with Anergis, a Switzerland-based clinical-stage biopharma company, to initiate a research study focused on the evaluation of the second-generation contiguous overlapping peptides allergen immunotherapy for birch pollen allergy.
In August 2018, HAL Allergy B.V. announced that it had got the marketing authorization for SUBLIVAC Birch 40.000 AUN/ml and SUBLIVAC Trees 40.000 AUN/ml in Germany. These two preparations are used for the treatment of allergic rhinitis and rhino-conjunctivitis in adults.
Competitive Landscape
ASIT biotech, Torii Pharmaceutical Co., Ltd., Arrayit Corporation, Stallergenes Greer Ltd., Sandoz Inc., HAL Allergy Group, DBV Technologies, ALK Abello A/S, Biomay AG, Aimmune Therapeutics, Allergy Therapeutics PLC, Jubilant Life Sciences Ltd., Merck KGaA, Adamis Pharmaceuticals Corporation, Circassia, Allergopharma, Anergis SA are some of the major players in the global Allergy Immunotherapy market.
